Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry
Executive Summary
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
You may also be interested in...
'Brands Don’t Die': Cipla Grabs Rights To Novartis’ Galvus In India
Novartis draws up perpetual license agreement with Cipla for its vildagliptin brand in India. Experts weigh in on some deal nuances and whether the DPP-4 inhibitor can deliver long-term value in an ultra-competitive segment.
How Cipla Is Aligning Manufacturing Amid The Pandemic
Cipla senior management executive tells Scrip how the company is calibrating manufacturing as part of a wider business “reimagination” and accelerated digital adoption across its operations.
Novo Nordisk’s New India Chief Steps Into Bustling Diabetes Arena
Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.